Notably, the relative treatment rankings for OS were not concordant with those observed for PFS, and the regimen achieving the highest OS ranking did not reach statistical significance.
← all excerpts
Network meta-analysis of first-line R-CHOP-based regimens in MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
2
—
—
The sentences
Only the Ven-R-CHOP signals (neutropenia, febrile neutropenia, anemia, and thrombocytopenia, together with any grade 3–4 adverse event and treatment discontinuation due to adverse events) and the ibrutinib hematologic signals (febrile neutropenia, anemia, and thrombocytopenia) retained significance after adjustment, whereas the remaining nominally significant findings—particularly those based on small samples or extreme OR values—are interpreted as exploratory and hypothesis-generating.